Efficacy of ETB-F01 in Patients with Respiratory Symptoms
Study Overview
Respiratory issues are common and can lead to serious health problems. This study focuses on a treatment called ETB-F01, which contains heat-killed Akkermansia muciniphila strain EB-AMDK19. We wanted to see if it helps reduce respiratory symptoms.
Trial Details
This was a randomized, double-blind trial involving participants with respiratory symptoms. They were treated with ETB-F01 or a placebo for 4 to 12 weeks. We measured:
- Breathlessness, Cough, and Sputum Scale (BCSS)
- Lung function
- Other respiratory-related questionnaires
Results
In the group that received ETB-F01:
- BCSS total scores improved significantly compared to the placebo group.
- Specifically, there was a notable reduction in breathlessness and cough.
- While lung function showed some improvement, it wasn’t statistically significant.
- No serious side effects were reported from ETB-F01.
Conclusion
ETB-F01 is safe and effective for reducing respiratory symptoms, providing a practical solution for patients.
Value of Clinical Trials
Clinical trials are essential for developing safe treatments. Our AI-driven platform, DocSym, helps integrate important medical standards and research into one easy-to-use resource for healthcare providers.
Enhancing Healthcare Operations
In today’s healthcare landscape, efficiency is key. Our mobile apps assist with:
- Scheduling appointments
- Monitoring treatments
- Telemedicine services
These tools help clinics improve patient care and reduce paperwork.
Learn More
Discover how we can support your practice at aidevmd.com.
